We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. The Administrator of personal data is STOCKTRADEIQ sp. z o.o., with its registered office in Poznan (61-625), at the following address: Czarna Rola 30 Street. Cookies policy here. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

  • Cookie
    cookieyes-consent
  • Duration
    1 year
  • Description
    CookieYes sets this cookie to remember users' consent preferences so that their preferences are respected on their subsequent visits to this site. It does not collect or store any personal information of the site visitors.
  • Cookie
    x-ms-cpim-csrf
  • Duration
    session
  • Description

    Inter-site request forgery token used to protect crSF. For more information, read the section Token falsification of requests between sites.

  • Cookie
    x-ms-cpim-sso:stocktradeiqauth.onmicrosoft.com_0
  • Duration
    session
  • Description

    Used to support single sign-on sessions. This cookie is set as persistent when the Keep me logged in option is enabled.

  • Cookie
    server-telemetry-{id}
  • Duration
    persistent
  • Description

    A value used by Microsoft for authorisation and authentication.

  • Cookie
    google_auto_fc_cmp_setting
  • Duration
    persistent
  • Description


    Stores the state of the User cookie for the current domain.

     

  • Cookie
    {id}-https://stocktradeiqauth.onmicrosoft.com/{id}
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    msal{id}.active-account
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com-refreshtoken
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com-idtoken
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    Microsoft Clarity
  • Duration
    1 year
  • Description

    Microsoft Clarity

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

  • Cookie
    isLightMode
  • Duration
    1 year
  • Description

    Defines the UI theme

  • Cookie
    userCultureData
  • Duration
    persistent
  • Description

     Stores information about the user's machine culture.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

  • Cookie
    _ga
  • Duration
    1 year 1 month 4 days
  • Description
    The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
  • Cookie
    _ga_*
  • Duration
    1 year 1 month 4 days
  • Description
    Google Analytics sets this cookie to store and count page views.
  • Cookie
    hotjar
  • Duration
    1 year 1 month 4 days
  • Description

    Analyzing users' behaviour in the website

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

  • Cookie
    __gpi
  • Duration
    1 year 24 days
  • Description
    Google Ads Service uses this cookie to collect information about from multiple websites for retargeting ads.
  • Cookie
    __gads
  • Duration
    1 year 24 days
  • Description

    The file, set by Google, is stored in the DoubleClick domain and tracks the number of times users view an ad, measures the success of the campaign and calculates its revenue. This cookie can only be read from the domain where it is set and does not track any data when browsing other sites.

  • Cookie
    goog:cached:topics
  • Duration
    persistent
  • Description

    It is used to record which adverts have been displayed to the User.

  • Cookie
    IDE
  • Duration
    year
  • Description

    Used by Google DoubleClick to record and report on the Website User's actions after viewing or clicking on an advertiser's ads in order to measure the effectiveness of the ad and present the User with targeted advertising.

  • Cookie
    google_experiment_mod44
  • Duration
    persistent
  • Description

    Used by Google Ad to experiment with the effectiveness of ads on websites using their services.

Powered by Cookieyes logo

    Get Diamond plan for FREE

    logo

    Mereo BioPharma Group plc (MREO)

    Price:

    2.19 USD

    ( + 0.01 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    MREO
    Name
    Mereo BioPharma Group plc
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    2.185
    Market Cap
    348.869M
    Enterprise value
    454.364M
    Currency
    USD
    Ceo
    Denise Vera Scots-Knight
    Full Time Employees
    36
    Website
    mereobiopharma.com
    Ipo Date
    2019-04-24
    City
    London
    Address
    One Cavendish Place

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Regeneron Pharmaceuticals, Inc.

    VALUE SCORE:

    6

    Symbol
    REGN
    Market Cap
    77.770B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    ADMA Biologics, Inc.

    VALUE SCORE:

    11

    Symbol
    ADMA
    Market Cap
    4.707B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Genmab A/S

    VALUE SCORE:

    11

    Symbol
    GMAB
    Market Cap
    123.304B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -7.051
    P/S
    223.025
    P/B
    6.448
    Debt/Equity
    0.011
    EV/FCF
    -8.906
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    187.530
    Earnings yield
    -0.142
    Debt/assets
    0.010
    FUNDAMENTALS
    Net debt/ebidta
    1.187
    Interest coverage
    -49.731
    Research And Developement To Revenue
    13.613
    Intangile to total assets
    0.008
    Capex to operating cash flow
    -0.001
    Capex to revenue
    0.013
    Capex to depreciation
    0.026
    Return on tangible assets
    -0.797
    Debt to market cap
    0.002
    Piotroski Score
    4.000
    FUNDAMENTALS
    PEG
    -0.071
    P/CF
    -10.611
    P/FCF
    -10.591
    RoA %
    -79.114
    RoIC %
    -84.050
    Gross Profit Margin %
    22.004
    Quick Ratio
    8.128
    Current Ratio
    8.128
    Net Profit Margin %
    -3.168k
    Net-Net
    0.316
    FUNDAMENTALS PER SHARE
    FCF per share
    -0.206
    Revenue per share
    0.010
    Net income per share
    -0.310
    Operating cash flow per share
    -0.206
    Free cash flow per share
    -0.206
    Cash per share
    0.351
    Book value per share
    0.339
    Tangible book value per share
    0.336
    Shareholders equity per share
    0.339
    Interest debt per share
    0.010
    TECHNICAL
    52 weeks high
    3.880
    52 weeks low
    1.470
    Current trading session High
    2.270
    Current trading session Low
    2.125
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo
    Country
    CH
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -5.070
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -4.846
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -27.805
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -17.480
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -5.482
    logo
    Country
    AU
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -8.740
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.940
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -3.710
    logo
    Country
    NL
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -5.546
    logo
    Country
    GB
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.769
    DESCRIPTION

    Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

    NEWS
    https://images.financialmodelingprep.com/news/traders-purchase-high-volume-of-put-options-on-mereo-20251212.png
    Traders Purchase High Volume of Put Options on Mereo BioPharma Group (NASDAQ:MREO)

    defenseworld.net

    2025-12-12 02:11:02

    Mereo BioPharma Group plc - Sponsored ADR (NASDAQ: MREO - Get Free Report) was the target of unusually large options trading on Thursday. Stock traders purchased 4,694 put options on the company. This is an increase of approximately 219% compared to the typical daily volume of 1,472 put options. Institutional Inflows and Outflows Hedge funds have

    https://images.financialmodelingprep.com/news/verde-agritech-confirms-ionic-adsorption-with-highvalue-magnet-rare-earths-20251021.png
    Verde AgriTech Confirms Ionic Adsorption with High-Value Magnet Rare Earths; Leachate MREO up to ~300 mg/kg with No Uranium Contaminant

    globenewswire.com

    2025-10-21 07:00:00

    SINGAPORE, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd. (TSX: NPK | OTCQX: VNPKF) ("Verde” or the “Company”), is pleased to report ionic-adsorption behaviour confirmed across multiple trenches at the Minas Americas Global Alliance Project (“Minas Americas” or the “Project”) in Minas Gerais, Brazil. Ammonium-sulfate leach tests returned primary leach solutions (“PLS”) with very strong magnet rare earth (neodymium (Nd), praseodymium (Pr), dysprosium (Dy), terbium (Tb)) grades and exceptionally low impurities (thorium/ uranium (Th/U) at, or below, detection).

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-20250903.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

    prnewswire.com

    2025-09-03 10:00:00

    NEW YORK , Sept. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO).

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mereo-20250825.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

    globenewswire.com

    2025-08-25 13:12:00

    NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mereo-20250822.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

    prnewswire.com

    2025-08-22 10:00:00

    NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mereo-20250821.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

    globenewswire.com

    2025-08-21 14:52:00

    NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/shibio-expands-clinical-pipeline-with-vantictumab-a-firstinclass-antibody-20250819.jpg
    āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2

    businesswire.com

    2025-08-19 08:30:00

    BURLINGAME, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced an exclusive licensing agreement with Mereo BioPharma (NASDAQ: MREO) for vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2), a rare, debilitating bone disorder with no approved therapies. The licensing of vantictumab represents a strategic expansion of āshibio's p.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mereo-20250816.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

    prnewswire.com

    2025-08-16 10:00:00

    NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mereo-20250813.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

    globenewswire.com

    2025-08-13 11:45:00

    NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/mereo-biopharma-reports-second-quarter-2025-financial-results-and-provides-20250812.jpg
    Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

    globenewswire.com

    2025-08-12 07:35:00

    Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027  LONDON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the second quarter ended June 30, 2025, and provided recent corporate highlights.  “We look forward to the final analysis for the two ongoing Phase 3 studies for setrusumab in osteogenesis imperfecta, the Phase 3 Orbit study in pediatric and young adult patients, and the Phase 3 Cosmic study in young pediatric patients, around the end of the year.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mereo-20250811.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

    prnewswire.com

    2025-08-11 10:00:00

    NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mereo-20250806.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

    prnewswire.com

    2025-08-06 10:00:00

    NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mereo-20250731.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

    prnewswire.com

    2025-07-31 10:00:00

    NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claimson-behalf-of-investors-of-mereo-20250728.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

    globenewswire.com

    2025-07-28 11:53:00

    NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.